Feeds:
Posts
Comments

Archive for the ‘Conference Coverage with Social Media’ Category


Venture Summit | West – “Where Innovation Meets Capital”, March 23rd & 24th  2020,

Santa Clara Convention Center, Silicon Valley

VSW20 – Discount code, LPBI-VIP and unique event site link http://bit.ly/2PfsbM7.

Video link for most recent event http://bit.ly/2LQpONN 

UPDATED on 1/16/2020

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to spons and invite you to join us at Venture Summit | West

Special offer:  Register Now & Save $450 off (Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23rd & 24th  2020

Santa Clara Convention Center, Silicon Valley

  

Reminder to register for the prestigious Venture Summit | West being held on March 23rd & 24th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track. Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies.

 

Whether you’re a Lifesciences/Healthcare startup seeking capital and exposure, or an investor seeking new deals, Venture Summit West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, Venture Summit | West is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 

Partial Initial Lineup of over 60 VCs & Angels confirmed to speak and judge includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Shaun Arora, Founding Partner, MiLA Capital | Shannon Austin, Partner, Financial Venture Studio | Jennifer Azapian, Partner , Mighty Capital | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Greg Bohlen, Managing Director, Union Grove Venture Partners | Peter Bruce-Clark, Partner, Social Impact Capital | Darren Cooke, Investor, Life Science Angels | Ross Darwin, Principal, Owl Ventures | Anne DeGheest, Founder, HealthTech Capital | Jun Deng, Partner, Joyance Partners | Robert Dunkle, President, ABES Venture Partners | Anna Fokina, Senior Associate, Data Collective | Norm Gitis, Managing Partner, Lymo Ventures | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Charlie Hanna, Investor, Marcy Venture Partners | Daniel Harris, Managing Director, DPH Ventures | Guy Horowitz, Partner, Deutsche Telekom Capital Partners | Jens Horstmann, Founding Director, Crestlight Ventures | Najib Khouri-Haddad, General Partner, Sway Ventures | Howard Ko, Principal, Morpheus Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ricky Lai, Principal, Portag3 Ventures | Anh Le, Partner, CRCM Ventures | James Lee, Investment Associate Director, Photon Fund | Darwin Ling, Founding General Partner, Good AI Capital | Melina Mathur, Principal, Asset Management Ventures | Manan Mehta, Founding Partner, Unshackled Ventures | SC Moatti, Managing Partner, Mighty Capital | Mark Mueller-Eberstein, Angel Investor, Alliance of Angels | Ivan Nikkhoo, Managing Partner, Navigate Ventures | Kira Noodleman, Principal, Bee Partners | Damien Petty, Principal, Morpheus Ventures | Patrick Pfeffer, Lead Investor, Juniper Networks | Bill Reichert, Managing Director, Garage Technology Ventures | Mario Ruiz, Investor, Paypal Ventures | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Gayatri Sarkar, Managing Partner, Hype Capital VC Fund | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Principal, Fort Ross Ventures | Li Sun, Partner, Foundation Capital | Erica Van, Investor, Charles River Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Elaine Zelby, Principal & Director of Growth, SignalFire | Stephanie Zepeda, Senior Associate, Arbor Ventures | Yanan Zhao, General Partner, Magnet Ventures | Sebastian Zhou, Investor, Alpha Square Group | Simin Zhou, VP & Managing Director, UL Ventures and many more.

 

 

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off. This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   (Use promo code “ LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

 We look forward to seeing you there. 

 

LPBI & youngStartup Ventures

 

 @@@@@@

Leaders in Pharmaceutical Business Intelligence (LPBI ) Group is pleased to announce its sponsorship and invite you to join us at Venture Summit | West

Special offer:  Register Now & Save $450 off

(Use discount code “LPBI-VIP”)

* Call for Top Innovators Details below

Venture Summit | West

Where Innovation Meets Capital

March 23rd & 24th  2020

Santa Clara Convention Center, Silicon Valley

  

Come meet, interact and network with more than 1,300 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit | West being held on March 23rd & 24th 2019 at the Santa Clara Convention Center. This year will again feature a dedicated Lifesciences/Healthcare Track.

 

Whether you’re a Lifesciences/Healthcare startup seeking capital and exposure, or an investor seeking new deals, Venture Summit West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, Venture Summit | West is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 

Lineup of over 150 VCs and Angels that spoke and judged at VSW19 includes:

Ben Abadi, Managing Director, Energy Innovation Capital | Navid Alipour, Co-founder and Managing Partner, Analytics Ventures | Logan Allin, General Partner & Founder, Fin Venture Capital | Kareem Aly, Principal, Thomvest Ventures | Magdi Amin, Investment Partner, Omidyar Network | Ash Archibald, Deal Principal, Wharton Angels | Jennifer Azapian, Partner , Mighty Capital | Carlos S. Baradello, General Partner, Alaya Capital Partners | Scott Beechuk, Partner, Norwest Venture Partners | Marcus Behrendt, Partner, BMW i Ventures | Lisha Bell, Dealflow Lead, Pipeline Angels | Ashish Bhatia, Angel Investor | Sunny Bia, Associate, CRCM Ventures | Mike Biddle, Managing Director, Evok Innovations | Alexa Binns, Associate, Maven Ventures | Wade Bitaraf, Founder, Energy & Sustainability, Plug & Play Tech Center | Tico Blumenthal, Co-chair of the Medical Device Screening Committee, Life Science Angels | Greg Bohlen, Managing Director, Union Grove Venture Partners | Will Borthwick, Senior Associate, Bold Capital Partners | Eric Breese, Investment Manager, Evonik Venture Capital | Maxx Bricklin, Founding Principal, Bold Capital Partners | Pratik Budhdev, Investment Director, Volvo Cars Tech Fund | Edouard Bulteau, Investment Manager, Total Energy Ventures | Andy Cao, Principal, Comcast Ventures | Packey Carrier, Investment Manager, American Express Ventures | Jeffrey Carter, General Partner, West Loop Ventures | Matthew Chavez, Associate, New Enterprise Associates | Joy Chen, Chief Investment Officer, TAL Education Group | Kelly Chen, Principal, Data Collective | Keting Chu, Venture Partner, LYFE Capital | Jackson Cummings, Investor, Salesforce Ventures | Michael D’Aurizio, Investment Manager, Centrica Innovations | Ned Daoro, Senior Associate, Clocktower Technology Ventures | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Partner, Joyance Partners | Dan Doble, Managing Director, SABIC Ventures | Rexhi Dollaku, Principal, Base10 | Yizhen Dong, Principal, 11.2 Capital | Ted Driscoll, Managing Partner, DigitalDX Ventures | Marah Dudenhoeffer, Manager, Verizon Ventures | Susannah Duke, Associate, Pelion Venture Partners | Robert Dunkle, President, ABES Venture Partners | Victor Echevarria, Principal, Jackson Square Ventures | Tom Eggleston, Managing Director , Charmides Capital | Geoffrey Eisenberg, Principal, Ecosystem Integrity Fund | Sean Engel, Principal, Top Tier Capital Partners | Michael Fanfant, Senior Associate, Runa Capital | Chenoa Farnsworth, Managing Director, Blue Startups | Kristen Faulkner, Associate, Threshold Ventures | Linda Fingerle, Partner, Tappan Hill Ventures | Spencer Foust, Principal, Sozo Ventures | Ben Freeberg, Senior Associate, Alpha Venture Partners | Chris Gaertner, Principal, Omega Venture Partners | Karim Gillani, General Partner, Luge Capital | Norm Gitis, Managing Partner, Life Science Angels | Garrett Goldberg, Partner, Bee Partners | Jocelyn Goldfein, Managing Director, Zetta Venture Partners | Daniel Gomez, Investment Analyst, Fusion Fund | Tyler Griffin, Managing Partner, Financial Venture Studio | Baris Guzel, Principal, BMW i Ventures | Perry Ha, Analyst, The Westly Group | Sheeraz Haji, Managing Partner, Zip Dragon Ventures | Daniel Harris, Managing Director, DPH Ventures | Laurence Hayward, Partner, Independence Equity | Annie Hazlehurst, Founder, Faridan | Alicia Castillo Holley, Investor, Sand Hill Angels | Jens Horstmann, Founding Director, Crestlight Ventures | Heyu Huang, Venture Partner, Fresco Capital | Anup Jacob, Co-Founder & Managing Director, Activate Capital Partners | Alexis Ji, Partner, Illumina Ventures | Gary Jinks, Founding Managing Director, South Valley Angels | Matt Jones, Managing Director, Solvay Ventures | Kathleen Jurman, Corporate Technology Scout, Dow Ventures | Amir Kabir, Investment Principal, Munich Re Ventures | Jimmy Kan, Senior Associate, Anzu Partners | Kester Keating, Head of US Strategic Investments, Barclays | Roger King, Founder, Bay Angels | Steve Kishi, Managing Director, Hummer Winblad Venture Partners | Yasemin Kliman, Co-President, Harvard Business School Angels | Daniella Kranjac, Co-Founder & Managing Director, Dynamk Capital | Nathan Krishnamurthy, Principal, Capital One Growth Ventures | Vivek Krishnamurthy, Associate, Commerce Ventures | Amit Kumar, Investor, Band of Angels | Kwasi Kyei, Associate, Sandbox Industries | Eduardo Laiter, Sr Investment Analyst, Kapor Capital | Severine Lalande, Investment Manager, Total Energy Ventures | Javaughn Lawrence, Investor, Eniac Ventures | Lindsay Lee, Managing Director, Authentic Ventures | Roberta Lee, Angel Investor, Life Science Angels | Sarah Lee, Investor, EdVentures Group | Julie Lein, Managing Partner, Urban Innovation Fund | Geraldine Le Meur, Founding Partner, The Refiners | Ephraim Lindenbaum, Managing Director, Advance Ventures | Alex Luce, Principal, Creative Ventures | Vincent Lui, Senior Director of Corporate Ventures, SK Telecom Americas | Silvia Mah, Executive Director and Founder, Hera Angels | Ashish Mahashabde, Investor, Amex Ventures | Shripriya Mahesh, Co-Founding Partner, Spero Ventures | Tasneem Manjra, Head of Network Development, Volvo Cars Tech Fund | Jillian Manus, Managing Partner, Structure Capital | Ben Metcalfe, Principal, Ridge Ventures | Wouter Meuleman, Director of Investments, Illumina Ventures | SC Moatti, Managing Partner, Mighty Capital | Linda Molnar, Program Director, National Science Foundation | Sasha Ostojic, Angel investor, Playground Global | Umesh Padval, Venture Partner, Thomvest Ventures | Hirak Parikh, Venture Partner, Augment Ventures | Victor Pascucci III, Managing Partner, Lightbank | Phoebe Peronto, Investor, Salesforce Ventures | Ricardo Politi, Partner, Mindset Ventures | Salil Pradhan, Venture Partner, Draper Nexus | Gagan Rana, Executive-in-Residence, Learn Capital | Peter Redford, Investor, Band of Angels | Bill Reichert, Managing Director, Garage Technology Ventures | John Ricci, Founder & Managing Partner, US Angels | Jennifer Richard, Senior Associate, Cross Culture Ventures | Andre Rocha, Investor, Glasswing Ventures | Riley Rodgers, Associate, Valia Investments | Peter Rojas, Founding Partner, Betaworks Ventures | Praveen Sahay, Managing Director, WAVE Equity Partners | Natalie Sandman, Senior Associate, Shasta Ventures | Miraj Sanghvi, Principal, DigiTx | Jason Schoettler, Co-Founder & Partner, Calibrate Ventures | Wes Selke, Managing Director, Better Ventures | Jayni Shah, Principal, Accomplice | Prashant Shah, Partner, Monta Vista Capita | Ann Shin, Founding Partner, Ultrafund Capital | Charles Sidman, Managing Partner, ECS Capital Partners | Kathleen Siswanto, Investor, Propel Venture Partners | Ira Smith, Director of Venture Investments, Pandect BioVentures | Tanya Soman, Venture Partner, 500 Startups | Shirley Speakman, Partner, Cycle Capital Management | Adam Spector, Angel Investor | Kumar Sripadam, Chair, TiE Global | Jack Statza, Senior Associate, Allstate Strategic Ventures | George Straschnov, Managing Director, Bisk Ventures | Marcus Stroud, Managing Partner, TXV Partners | Mayra Tama, Principal, Initial Capital | Wei Tao, Life Science Angels, Chair Bio Genomics Committee | Craig Taylor, General Partner, Alloy Ventures | Laura Thompson, Principal, Sapphire Ventures | Vishal Verma, General Partner, Edgewood Ventures | Che Voigt, Chairman, North Bay Angels | Jordan Wahbeh, Managing Director, Bay Angels | Timothy Wang, Principal, The Westly Group | Kyoko Watanabe, Managing Director, DEFTA Partners | Patricia Wexler, Co-Founder & Managing Director, Starlight Ventures | James Wu, Senior Associate, M12 | Jonathan Wu, Board Director and Vice President, Sand Hill Angels | Margaret Wu, Investor, Georgian Partners | Veronica Wu, Managing Partner, Hone Capital | Wei Wu, Healthcare Investment Director, BOE Ventures | Matthew Wukasch, Managing Director, Charmides Capital | Wenz Xing, Associate, Bullpen Capital | Sue Xu, Managing Partner , Amino Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Jimmy Zhu, Vice President, Citi Ventures | Shelley Zhuang, Founder and Managing Partner, 11.2 Capital | TX Zhuo, Managing Partner, Fika Ventures and many more.

 

 

Special Offer:

LPBI has made special arrangement for our network to receive a special discount of $450 off.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   (Use promo code “ LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

  • Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

  • Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

 We look forward to seeing you there. 

 

LPBI & youngStartup Ventures

 

LPBI Group – Executive Summary

The Challenge

“Today, there is a digital information explosion in the fields of Life Sciences and Medicine,” said Aviva Lev-Ari, Ph.D., R.N., and founder of Leaders in Pharmaceutical Business Intelligence (LPBI) Group. “To manage that challenge, we are responding to the needs of our multi-faceted audiences in order to guard against information obsolescence through transformational technologies and solutions.”

 

Our Vision:

LPBI Group generates vast scientific content via industry thought leaders through multiple platforms and makes it universally accessible.

 

About LPBI Group

Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is a leading, electronic scientific content-creation venture, offering real-time, original scientific content through advanced platform architecture methodologies since 2012. The company’s commitment is to synthesize, analyze and interpret complex, medical and scientific disease information through electronic publishing venues via the cloud to advance the knowledge and research efforts of the scientific and business community.

LPBI Group was created in 2012 by Dr. Aviva Lev-Ari, Ph.D., R.N. The Group has evolved into three, interrelated domains – an open-access online scientific journal, a series of 16 BioMed e-books and real-time press coverage of BioMed scientific and medical conferences. Through this transformative offering, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any subject as well as cutting-edge biomedical research innovation widely available to the scientific and non-research community. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Year over year, there is increased readership of highly valued content, which equates to more than 5,500 scientific articles with over 1.6 million readers in the online scientific journal.

 

Unique, Experienced Team

The Group employs a team of highly experienced individuals in Life Sciences, particularly within the key domains of BioMedicine, Biotechnology, Pharmaco-therapy, Medical and Information Technology, Health Care and the Life Sciences/Medicine connection.

All members of the LPBI Group team have a wealth of expertise and experience in Life Sciences and have been trained to master the methodology of scientific curation used in the articles. Those individuals include senior MDs, MD/PhDs, PharmDs and senior PhDs who expressed interest in medical writing and clinical interpretation of basic research, translational research and interpretation of clinical trials outcomes.

  • Medical Doctors: Dr. Larry H. Bernstein (retired), Dr. Justin Pearlman (Central Maine Medical Center)
  • Doctors of Philosophy: Dr. Justin Pearlman, Dr. Stephen Williams, Dr. Sudipta Saha, Dr. Ritu Saxena, Dr. Tilda Barliya, Dr. Irina Robu, Dr. Dror Nir, Dr. Aviva Lev-Ari
  • Professors in Academia: Prof. Marcus W. Feldman (Stanford University), Prof. Stephen J. Williams (Temple University), Prof. Sudipta Saha (Amity University Noida, Uttar Pradesh, India), Dr. Irina Robu (Windsor, Ontario, Canada), Adam Sonnenberg, PhD(c), Boston University
  • Executives in Biotechnology and Information Technology Industries: Amnon Danzig, MBA, Europe-Asia (business development consultant with specialization in Strategy, Corporate Finance and Human Capital, published author on Value Creation concepts), Rick Mandahl, MBA, Americas (business development consultant in emerging technologies with Biotech, Information Technology focus), Ritu Saxena (Astellas Pharma), Gail S. Thornton, M.A., PhD(c), (Merck & Co., USA, communications consultant, published author on health, wellness, communications strategy)

 

Scientific e-Books Source

The 16 BioMed e-books include topics focused on medical science, diagnostics and therapy. The books’ sustainability is maintained by online continuing updates made to articles in the online scientific journal. Each of the scientific e-books contain an abbreviated electronic table of contents, which consists of ‘live’ links from each article in the e-book to the article in the online scientific journal. Readers of the e-books can click on this link to receive the most, updated “State of Science” for each topic. This unique feature makes the e-books relevant and provides a timely source of knowledge and reference.

Highly qualified content consultants, who are senior MDs, MD/PhDs and Professors, are involved in the production and clinical interpretations of the curations. The topics for curation and the contents of the books are uniquely created and carefully edited. Dr. Aviva Lev-Ari as the editor-in-chief leads this multidisciplinary content compilation using her diverse areas of technical training and experience. It should be noted that all of LPBI’s material could, in principle, be translated into other languages.

 

Journal Ontology

Our intellectual property consists of three classes of Intellectual property assets as described in detail with live links in the following article:

eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

https://pharmaceuticalintelligence.com/2019/02/04/escientific-publishing-a-case-in-point-evolution-of-platform-architecture-methodologies-and-of-intellectual-property-development-content-creation-by-curation-business-model/

 

Three Classes of Intellectual Property Assets

These assets include an open-access online scientific journal with curated, current biomedical research; a series of 16 BioMed e-books available via Amazon in five specialties of Medicine: Cardiovascular, Genomic Medicine (a subset of Precision Medicine), Cancer, Immunology and Precision Medicine; and real-time curation of biotech and medical conferences yielding an e-Proceedings at the end of the conference in one click operation.

For example, Genomic Medicine, as an emerging medical discipline, is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases and infectious disease. This field involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use.

The open-access online scientific journal ontology is a relational and hierarchical knowledge base allowing for expansion of the content creation process between the journal and the series of BioMed e-books, but it is not limited to these two areas. For example, one of the research categories, entitled “Interviews with Scientific Leaders,” includes in its growth plan the option of podcasts, an audio media component that will supplement the video media component used extensively in the BioMed e-Series.

The Group’s business is scalable, and the skill set needed for curation of scientific findings for clinical interpretations, as well as in other disciplines can be augmented by appropriate training in the curation methodology to be offered to experts in many fields. In our seven years together, the Group’s writers and editors generated a remarkable synergy among experts, authors and writers, which yields outstanding collaboration in producing these curations. There are many post-doctoral individuals in the biotechnology industry as well as academia who can serve as experts, authors and writers in continuing the Group’s operations, following appropriate onboarding.

Contact us

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, NJ, Salt Lake City, Berkeley, Cambridge UK, Maine, New Delhi, Palo Alto, Philadelphia, Toronto

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

Read Full Post »


Tweets and Retweets by @pharma_BI and @AVIVA1950 for #NEVS at 2019 New England Venture Summit, December 4, 2019 at the Hilton in Boston, Dedham, MA, hosted by youngStartUp #NEVS

 

Event Agenda

https://pharmaceuticalintelligence.com/2019/07/23/2019-new-england-venture-summit-december-4th-2019-at-the-hilton-in-boston-dedham-ma-hosted-by-youngstartup-nevs/

liked your Tweet

#NEVS19 @pharma_BI @AVIVA1950 #AI strategic investment high tech ventures are long term for VC and founders milestones entrepreneurs need to meet for BC To accept valuation board controlled by Entrepreneur or by VCs convertible 15% discount negotiation power at product stage vary pic.twitter.com/WxNuRMGn8l

liked your Tweet

We are in the Cloud only #NEVS19 @AVIVA1950 @pharma_BI twitter.com/stevesherlock/

liked your Tweet

#NEVS19 #pharma_BI @AVIVA1950 Mediktor is SAAS B2B in 12 languages need $5-$15M access to Health Care pic.twitter.com/RadPqiAZj6

liked 18 of your Tweets

#NEVS19 @pharma_BI @AVIVA1950 Asymmetrex stem cell counter service model need to establish cell culture lab improve SW automation establish ASTM standard achieve FDA guidance pic.twitter.com/z14Yes3tL9

Show all

liked your Tweet

#NEVS19 @pharma_BI @AVIVA1950 #VC #Investors are presenting the #pulse #investment #market #institutionalInvestors #Ecits #IPO by #M&A #women #leaders #platform #investment #corporate #technology #gamechanging #Entrepreneur #raisingfunds 12-18 month #economic #downturn #deals pic.twitter.com/fFdOQphhsd

Aviva Lev-Ari
@AVIVA1950

Great panel over 120 years of #investment #experience guiding young #entrepreneurs #NEVS19@pharma_BI

Quote Tweet
Gayatri Sarkar 

🌴

🌏

⌛️

@GS_VCactivist
·
I had such a great time talking about “Art of Negotiating Termsheets” with @XFactorVentures @AMD ventures @goodaicapital Millenium Technology Value Partner and @NexusVP at #NEVS19

Image

Image

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

who are the customers vs focus on technology and products great technology can fail because management is not aligned technologies can not get traction due to slow adoption in the market optimized valuation take partners long term cost structure

Image

James L. Sherley
@asymmetrex

Asymmetrex at the New England Venture Summit today in Boston(#NEVS19). A featured Life Sciences presenter for stem cell counting.
James L. Sherley, M.D., Ph.D. on LinkedIn: #NEVS19
Asymmetrex at the New England Venture Summit today in Boston(#NEVS19). A featured Life Sciences presenter for stem cell counting….
linkedin.com
1
2

Vivonics Inc.
@VivonicsInc

Vivonics / CranioSense CEO Gordon Hirschman at the #NEVS19 New England Venture Summit, seeking investment for IPASS, our medical device for non-invasive assessment of intracranial pressure (ICP), critical in traumatic brain injury (TBI), stroke and other brain conditions.

Image

1
3

Medigate
@MedigateLtd

Jonathan Langer, CEO of

, spoke with

to share his predictions for #IoT trends in 2020. Read the article here: tek.io/35zIUiC. #cybersecurity

Image

1
10
18

Aviva Lev-Ari
@AVIVA1950

#NEVS19

#AI strategic investment high tech ventures are long term for VC and founders milestones entrepreneurs need to meet for BC To accept valuation board controlled by Entrepreneur or by VCs convertible 15% discount negotiation power at product stage vary

Image

1
2

Aviva Lev-Ari
@AVIVA1950

#NEVS19

spin off @BOSTONUniversity microscopy based ExoBiew #exsosome cell communication Luminex is competitor companion diagnostics liquid Biopsy pancreatic cancer @ BIDMC interrogate exosome for therapeutics another exosome sold for $330M

Image

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Session on angel investing, interesting insights e.g. be transparent! #nevs19 #startups #pitchdeck

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

who are the customers vs focus on technology and products great technology can fail because management is not aligned technologies can not get traction due to slow adoption in the market optimized valuation take partners long term cost structure

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

SIG.NUM SIG.RHYTHM SIG.12-LED #ECG alternative technology to 12 leads a pad with sensors

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

spin off @BOSTONUniversity microscopy based ExoBiew #exsosome cell communication Luminex is competitor companion diagnostics liquid Biopsy pancreatic cancer @ BIDMC interrogate exosome for therapeutics another exosome sold for $330M

Image

1
1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

@ABIVA1950

MICROSCOPY INDUSTRY Microdissection market life science research platform open platform for Re-agent companies Cartridge removable Live Cell imaging market need $5M

Image

1
1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

micro needles for diagnostics using ISF #Interstitial System Fluid uses #glucose, #allergy, #neonatal

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

Asymmetrex stem cell counter service model need to establish cell culture lab improve SW automation establish ASTM standard achieve FDA guidance

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

FIRST LIGHT DIAGNOSTICS antibiotics resistance C-Diff MRSA Rapid AST Anti microbial susceptibility Testing B Round pre Revenue small valuation

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

device requires less energy than LVAD no support continuous mode pulsitile mode Euro16M needed to complete animal trials

Image

1

Aviva Lev-Ari

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Quote “I never invest in part time founders” and “If you can’t commit full time you shouldn’t be raising money” #startups #vc #angel #nevs19

Aviva Lev-Ari
@AVIVA1950

#NEVS19

micro needles for diagnostics using ISF #Interstitial System Fluid uses #glucose, #allergy, #neonatal

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

device requires less energy than LVAD no support continuous mode pulsitile mode Euro16M needed to complete animal trials

Image

1

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Quote “I never invest in part time founders” and “If you can’t commit full time you shouldn’t be raising money” #startups #vc #angel #nevs19

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

Aviva Lev-Ari
@AVIVA1950

Image

2

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

SIG.NUM SIG.RHYTHM SIG.12-LED #ECG alternative technology to 12 leads a pad with sensors

Image

Read Full Post »


Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

see also,

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

https://pharmaceuticalintelligence.com/2019/07/19/15th-annual-personalized-medicine-conference-at-harvard-medical-school-the-paradigm-evolves-november-13-14-2019-%e2%80%a2-harvard-medical-school-boston-ma/

 

 

Tweets by @AVIVA1950 and by @pharma_BI

Aviva Lev-Ari
@AVIVA1950

#PMConf

Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, UPenn’s Perelman School of Medicine no relations explored between Immune T cells and microbiome

2
1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Impact of Mirobiome it plays a key role in many diseases difficult to develop therapeutics derived from microbiome data

1
1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Harpreet Singh, Ph.D., CEO, Immatics T Cell peptide started 15 years ago Peptonomics,  tumors of solid cancer – cell therapies selected from libraries  off the shelf cells from health donors Biologics bridges tumor cells and solid cells

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, UPenn’s Medicine CAR-T therapy started the Transfusion Medicine & Therapeutic Biology industry

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Combination therapy emerges, MOA partnerships: cell therapy can transform cancer treatment INFECTIOUS disease had Global impact need stop the virus

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., #CSO

Platforms are established, every 20-30 another one emergences access to data – critical platform AI for diagnostics and decision making biomarkers J&J try to learn on every disease: Lungs and GI Diagnosis HIV Vaccine

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Goals of medicine in 2019 early detection Vaccines in disease prevention Longevity

Aviva Lev-Ari
@AVIVA1950

#PMConf

Joseph B. Martin, M.D., Ph.D., Dean Emeritus

fascinating personal history story on development of interest in genetic analysis

Aviva Lev-Ari
@AVIVA1950

#PMConf

Michael J. Pellini, MD Diagnostics Pain management  Patients can fight more broadly F for sharing data and data exchange 80% patients do not access Academic Centers for treatment

Aviva Lev-Ari
@AVIVA1950

#PMConf

Michael J. Pellini, MD surgery, chemo, radiation – cost, harmful, INEFFECTIVE, Dr. Reza Columbia Medical School Oncologist 35 years How are we doing with technology? Very remarkable Clinical Utility to the Payer Regulatory – a super star in ten years

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn Beyond Cancer: Chronic diseases have systemic of specific immune or autoimmune components: CNS, neurodegenerative and Diabetes, Sickle cell anemia – treatment by cell therapy microphages

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn Cost of cell transfection therapy: Cost of Goods, Cost of Labor – pay for performance,  Manufacture in NJ shipped to Europe – not effective

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn Similarity between Transfusion Medicine industry and Cell therapy – Transfection of cells therapy  Manufacturing of Cells for transfection: Over regulation like in small molecules vs too little regulation

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn engineering T cells life farming – innovation is the driver, FDA is evolving in handling patents involved in Cell engineering Regulatory science needs to evolve in light of gene therapy in Human cell line in China

Aviva Lev-Ari
@AVIVA1950

#PMConf

Stephen L. Eck, Carl June, UPenn Children vs Adults 2011 reported better results in Adults, children’s immune system is evolving  In 2019 – 13 biotech companies in CAR-T cell therapies, Gene therapy is growing FDA, drug cycle T cells vs stem cells

Aviva Lev-Ari
@AVIVA1950

#PMConf

15th Annual meeting is at a historic moment in Boston where Prof. Church launched the Human Genome Project and Eric Launder at MIT and the Cancer Genome Project. Genzyme conceived gene therapy sold to Sanofi for $ Billion  Foundation Medicine

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Edward Abrahams, Ph.D., President, PMC 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy Gene therapy started in 2005, today personalized medicine is becoming standard of care. Science & Technology need additional friendly environment

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Kenna R. Mills Shaw, Ph.D., MD Anderson Institute does not sequence genome of each patient unlike Dana Farber clinicians need to access information for decision making when disease progresses – what new test to order data sharing inside the institute

Aviva Lev-Ari
@AVIVA1950

#PMConf

Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, PMC Genomic sequencing for a single test that covers many biomarkers Improve treatment efficiency Growing recognition of the need to demonstrate value, evidence for Payers to pay

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Ammar Qadan, Vice President, Global Head of Market Access, Illumina Illumina is building evidence for Harvard Pilgrim on theirs patient data on risk pregnancies Illumina is expanding  building evidence for ALL rare diseases for all Test diagnostics

Aviva Lev-Ari
@AVIVA1950

#PMConf

Roy J. Gandolfi, M.D., Medical Director, SelectHealth, UT is the Payer of Intermountain Healthcare, UT Regional approach vs National perspective medical policies requires experts for Payer to approve a treatment Consumer in the health plan

Aviva Lev-Ari
@AVIVA1950

#PMConf

Lincoln Nadauld, M.D., Ph.D., Chief, Precision Health, Intermountain Healthcare, UT Precision Oncology Program: Need, study, analysis outcome, publish dataPharmacogenetics testing will be covered for all employees & Neonatal

Aviva Lev-Ari
@AVIVA1950

#PMConf

Peter J. Neumann, Sc.D., Tufts Medical Center clinical utility evidence of value: saving by diagnostics cost for quality cost of diagnostics cost effectiveness – characterize utility cost effectiveness – study Value to families value of knowledge

Aviva Lev-Ari
@AVIVA1950

#PMConf

Ammar Qadan, Vice President, Global Head of Market Access, Illumina Illumina is partnering with providers and Payer Illumina & Blue Cross Blue Shield 150 Million are covered for genomics 2500 genomics test done Under utilization educate physician

Aviva Lev-Ari
@AVIVA1950

#PMConf

Mark P. Stevenson, COO Thermo Fisher Scientific Context: Therapy selection in personalized medicine navigate diagnostics in use and policies when implementations is considered Physicians need precise testing now Payers evidence of utility is needed

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific Patient Outcome – Data analytics, ML, AI for genomics, proteomics, metabolomics, Tests must be precise and inform the diagnosis by diagnostics Solutions

Aviva Lev-Ari
@AVIVA1950

#PMConf

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Passion of Scientists pharmaceutics development is based on insights looking into the future – important goal to solve

Aviva Lev-Ari
@AVIVA1950

#PMConf

best conference on Personalized Medicine in 15 years eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM…
eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA   The 15th Annual …
pharmaceuticalintelligence.com

Aviva Lev-Ari
@AVIVA1950

Your synopsis of the best Personalized Medicine Conference organized to date #PMConf

Quote Tweet
Aviva Lev-Ari
@AVIVA1950
·
#PMConf @pharma_BI @AVIVA1950 best conference on Personalized Medicine in 15 years eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA pharmaceuticalintelligence.com/2019/07/19/15t

 Retweet by @AVIVA1950

Aviva Lev-Ari
@AVIVA1950

A true leader in Pharmaceutical domain, also Member of the National Academy of Art and Sciences #PMConf

Quote Tweet
Cynthia Bens
@bens_cynthia
·
Introducing the amazing @ScottGottliebMD was a highlight of #pmconf. His vision for balanced regulatory and coverage policies is desperately needed now to support the future of #personalizedmedicine @permedcoalition

Image

Aviva Lev-Ari
@AVIVA1950

#PMConf

Best Case study

Quote Tweet
PMC
@permedcoalition
·
This year’s #PMConf case study on the @TheDDFund puts a spotlight on what one can do to combine modern entrepreneurial finance approaches to tackle a very complex problem such as Alzheimer’s Disease. @RHamermesh @HarvardHBS #PMConf

Image

Aviva Lev-Ari
@AVIVA1950

#PMConf

Edward Abrahams, Ph.D., President, PMC 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy Gene therapy started in 2005, today personalized medicine is becoming standard of care. Science & Technology need additional friendly environment

1

Genomic Health®
@GenomicHealth

We’re proud to announce Steve Shak is the recipient of the Leadership in Personalized Medicine Award at the 15th Annual Personalized Medicine Conference: The Paradigm Evolves. Please come and see him speak at the conference. bit.ly/2lMAteZ #PMConf

Image

1
7

Read Full Post »


DISCOVER BRIGHAM | NOVEMBER 7, 2019, 10AM – 6PM

#DISCOVERBRIGHAM

@pharma_BI

@AVIVA1950

 Aviva Lev-Ari, PhD, RN will be attending and will cover presentations in real time

ABOUT BRIGHAM RESEARCH

Discover Brigham is hosted by the Brigham Research Institute (BRI), under the umbrella of Brigham Health. Launched in 2005, the BRI’s mission is to accelerate discoveries that improve human health by bridging the gaps between science, communication and funding. The BRI’s resources help to foster groundbreaking interdepartmental and interdisciplinary research. They provide a voice for the research community and raise the profile of Brigham Research.

Speakers

http://www.discoverbrigham.org/speakers/

 

AGENDA

http://www.discoverbrigham.org/agenda/

ASK A QUESTION WITH SLI.DO!

DO YOU WANT TO SUBMIT A QUESTION TO A SPEAKER OF A SESSION? YOU CAN DO IT THROUGH SLI.DO!

2. ENTER THE EVENT CODE: DB19. THEN HIT JOIN!
3. PICK THE SESSION YOU WANT TO ASK A QUESTION. THEN ASK YOUR QUESTION!
4. YOUR QUESTION WILL BE REVIEWED AND MAY BE FORWARDED TO THE CHAIR TO ASK THE SPEAKER(S).

IT WORKS ON ANY DEVICE, YOU DO NOT NEED TO INSTALL ANYTHING!

 

Registration will open at 9:00 AM and will be located throughout the hospital including

  • Schlager Atrium (formerly known as Cabot Atrium, 45 Francis Street Lobby),
  • Schuster Lobby (75 Francis Street Entrance),
  • Shapiro Cardiovascular Center (70 Francis Street Entrance), and the
  • Hale Building for Transformative Medicine (HBTM) 1st Floor (60 Fenwood Road).

 

Click here for directions to these locations.  

NAVIGATING THE BRIGHAM IS EASIER THAN EVER

Need directions to a clinic, conference room, public space, or help assisting someone who looks lost?

Try our browser-based wayfinding tool and mobile app, BWH Maps,
which provides real-time location tracking and directions in the hospital.

Look for BWH Maps on the Apple App Store and Google Play Store,
or visit maps.brighamandwomens.org.

REGISTRATION LOCATIONS

Please visit one of the registration desks listed below to check-in, receive your badge, and collect any necessary materials. Registration will begin starting at 9:00 AM at each of the locations below.

 

Click on each location below for directions. 

  • SCHLAGER ATRIUM, FORMERLY KNOWN AS CABOT ATRIUM (45 FRANCIS ST. LOBBY)
  • SCHUSTER LOBBY (75 FRANCIS ST. LOBBY)
  • CARL J. AND RUTH SHAPIRO
    CARDIOVASCULAR CENTER
  • HALE BUILDING FOR
    TRANSFORMATIVE MEDICINE

SESSION LOCATIONS

Below you will find directions to each of the session locations.

MARSHALL A. WOLF CONFERENCE ROOM

HALE BUILDING FOR TRANSFORMATIVE MEDICINE

SESSION ROOM

FROM 60 FENWOOD ROAD:
Enter at 60 Fenwood Rd lobby entrance.

STAIRS:
Take the lobby staircase to the 2nd floor. Walk past the balcony overlooking the atrium and take the stairs on the left (Stair 2) to the 3rd floor. Once on the 3rd floor, exit the stairwell and take a right. The room is to your right through the double glass door, straight ahead.

ELEVATOR:
Take S Elevator to 3rd floor. Take a right out of the elevator. The room is past the stairwell, on your right through the double glass doors.

HALE VTC 02006B CONFERENCE ROOM

HALE BUILDING FOR TRANSFORMATIVE MEDICINE

OVERFLOW ROOM FOR MARSHALL A. WOLF CONFERENCE ROOM

FROM 60 FENWOOD ROAD:
Enter at 60 Fenwood Rd lobby entrance.

STAIRS:
Take the lobby staircase to the 2nd floor. The conference room will be on your right near the display monitor.

ELEVATOR:
Enter at 60 Fenwood Rd main entrance and take the S Elevator to the 2nd floor. Once you exit the elevator, take a right and walk past the balcony overlooking the atrium and the conference room will be straight ahead near the display monitor.

ZINNER BREAKOUT ROOM

CARL J. AND RUTH SHAPIRO CARDIOVASCULAR CENTER

SESSION ROOM

FROM 70 FRANCIS STREET:
The Zinner Breakout Room is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalators in the rear of the building. The Zinner Conference Center is located on your right; the Breakout room is through the large doors on the left.

ZINNER BOARDROOM

CARL J. AND RUTH SHAPIRO CARDIOVASCULAR CENTER

OVERFLOW ROOM FOR ZINNER BREAKOUT ROOM

FROM 70 FRANCIS STREET:
The Zinner Boardroom is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalator, keeping to the left side of the building. The Conference Center is located on your right; the Boardroom is through the large doors on the back wall.

BORNSTEIN FAMILY AMPHITHEATER

MAIN PIKE, 45 FRANCIS STREET LOBBY

SESSION ROOM

FROM 45 FRANCIS STREET:
Coming from 45 Francis Street lobby, walk towards the Main Pike (2nd floor hallway). Then take left on the Main Pike, 2nd door on right.

AGENDA

10:00 AM – 11:00 AM

Opening remarks

Elizabeth G. Nabel, MD, President Brigham Health, Prof. Medicine @HarvardMed

  • 8th event since 2012
  • show casing amazing research
  • Open to the Public: Patients, Families to educate
  • 90 Posters
  • Health equity perspective as DNA of the Brigham
  • Learn a new idea, meet someone new, create a new idea

Keynote Introduction

David Bates, MD @DBatesSafety

KEYNOTE

KYU RHEE, MD, MPP, VICE PRESIDENT & CHIEF HEALTH OFFICER, IBM CORPORATION & IBM WATSON HEALTH

MAIN PIKE, 45 FRANCIS STREET LOBBY
  • Partnership BWH & IBM WATSON
  • Big data of claims from providers to payers
  • Waiting rookms in Healthcare delivery
  • Government: ACA
  • AI Spring is here, no more Winter for AI
  • Health disparities, salaries, sexual orientation – improving health of populations
  • Science & Security
  • Red Hat – data security – big data statoscope
  • Healthcare Culture & Technology Culture: IBM & Amazon hire healthcare professionals
  • Cost: Burnout, managing population health,
  • Reduce physicians burnout
  • Culture Tech – Competition by IBM’s Project Debater

11:15 AM – 12:50 PM

1:00 – 1:50 PM

FROM 70 FRANCIS STREET:
The Zinner Breakout Room is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalators in the rear of the building. The Zinner Conference Center is located on your right; the Breakout room is through the large doors on the left.

Aaron Goldman
HaeLin Jang
Greog K. Gerber
  • Microbiome – Bacteria and Fungus therapies – computational tools for applications on microbiome
  • Diagnostics
  • Microbiome in early childhood
  • temporal variability during adulthood
  • host disease bacteriptherapeutics: C-Diff
  • Bugs as drugs
  • Gnotobiotic mice model for c-Diff in mice
  • MDSINE – Microbial dynamin model interaction model
  • cancer microbiome: Bacteria causing cancer, cancer changing the bacteria environment

 

Jeff Karp BENG PhD @MrJeffKarp

  • tissue based patch to seal open foramane ovale. Project remained in Academic settings however
  • GLUE component was commercialized
  • bioinspiration from living organs in Nature, slugs
  1. Viscose secretions
  2. Hydrophobic secretions and snails and sand castle worms

1:00 – 1:50 PM

Lina Matta, PharmD
Joji Suzuki, MD
Lisa WIchmann
Kevin Elias, MD
Daiva Braunfelds,MBA HPH
Elizabeth Cullen, MS

2:00 – 2:50 PM

3:00 – 3:50 PM

David Levin
Christopher baugh
Kathryn Britton
Joanne Feinberg Goldstein
Amrita Shahani
If patient meets criteria for Home Hospital : all services are sent home.
2016 – Pilot randomized controlled trial
2017-2018 – Repeat of Pilot on larger population
2018 – High-volume single arm innovation services
2019 – studies within home hospital wtth sensors at home
2020 – continue
Operation and Research lead to innovations

Anna Krichevsky, PhD HMS Initiative for RNA Medicine

  • paradox of organismal complexity and # protein encoding genes
  • Human genome, 70% Transcriptome Non-coding RNA only 2% encode proteins
  • Non-coding RNA small, long, multifunctional
  • biogenesis of offending RNAs can be drugged
  • RNA novel therapies: RNA as a Drug,
  • Indications: Brain Tumors and AD: MicroRNA (miRNA)the smallest Glioblastoma – only 4 drugs FDA approved in 25 years miRNA – 10b inhibition kills gliomacells miR-132 most neuroprotective RNA
  • Cardiovascular

Paul Anderson, MD, PhD

  • ALS and FTD – Fronto Temporal Dimensia
  • Riluzone 1970 – anti Anti-glutamateric
  • Edarabone 2017 drugs approved – anti-oxidative
  • Andogenesis role in Motor protection from Stress Cytoplasmatic tRNA – ANdiogenin (ANG) production
  • 20 amino acids
  • 5″-tiRNAs assemble G-quadruples – G4
  • point mutationin ANG (mANG) reduce its RNanase
  • G4-containing DNA analogs of 5″-tiRNA (Ala)

Marc Feinberg, MD

  • Cardiovascular: CAD, Insulin resistence – Vascular inflammation
  • Impaired angiogenesis: post MI repair CHF
  • MiRNA therapeutics for Atherosclerosis – miR-181b: Aortic ECs Athero (mice) CAD (Human)
  • miRNA _ Liposomes injected in the vessel wall – reduction of inflammation in vessel – microRNA Group
  • monocyte – How can we increase or amintain mir-181b expression in endothelial cells?
  • LncRNA Therapeutics for vascular Senescence and Atherosclerosis – no effect on leucocyte accumulation no difference in inflammation
  • DNA-dependent protein kinase (DNA-PK)
  • Does Loss SNHG12 triggers vascular senescence in the vessel wall

 

Clemens Scherzer, MD

  • The Protein RNA Brain
  • Dopamin p
  • BRAINCODE: 64% RNA: mRNA, ncRNA,
  • cell-type-spacific putative enhancer RNAs (eRNAs)
  • eRNAs indicate active genetic switches
  • central dogma in Biology: DNA, non-coding RNA, Protein
  • Top 10 Markers
  • Neuropsychiatric Disease: Parkinson: How do genetic variants function in specific brain cells: neurons, microglia, astrocytes
  • genetic variants of neuropsychiatric diseases over-localize to active eRNA sites in dopamine neurons
  • enhancers RNA – ADHD,
  • enhacers RNA – schizoprania, bipolar, addiction – antopsychotic Vlporic acid
  • BRAINCODE Project: BWH MGH HMS

5:00 – 6:00 PM

AWARDS & RECEPTION

SPECIAL PHOTO-OP TO CELEBRATE YOU!
WE WILL TAKE A GROUP PHOTO DURING THE RECEPTION AND AWARDS CEREMONY TO CELEBRATE YOU, OUR INNOVATORS!
THE PHOTO WILL BE DISPLAYED AT THE BRIGHAM IN THE HALE BUILDING. WE HOPE YOU CAN JOIN US IN CELEBRATING YOUR ACHIEVEMENTS.

SOURCE

http://www.discoverbrigham.org/agenda/

Read Full Post »


@CHI 1st AI World Conference and Expo, October 23 – October 25, 2019, Seaport World Trade Center, Boston, MA.  Presentations by Four Israeli companies explaining how they use AI technologies in their products @ NEIBC Meetup AI World Conference and Expo, 10/24/2019 @6:30PM Waterfront 1

#AIWORLD

@AIWORLDEXPO

@pharma_BI

@AVIVA1950

Reporter: Aviva Lev-Ari, PhD, RN

 

  • When: October 24, 2019
  • Time: 6:30 pm
  • Where: Seaport World Trade Center, Boston, MA
  • Room Location: Waterfront 1

Speakers Includes:

Registration:

  • To gain access to NEIBC Meetup please RSVP below and use code 1968-EXHP and get complimentary pass to the exhibit
  • If you want to attend the conference, use NEIBC19 discount code and get $200 off conference registration

RSVP NOW

AI World Conference and Expo has become the industry’s largest independent business event focused on the state of the practice of AI in the enterprise. The AI World 3-day program delivers a comprehensive spectrum of content, networking, and business development opportunities, all designed to help you cut through the hype and navigate through the complex landscape of AI business solutions. Attend AI World and learn how innovators are successfully deploying AI and intelligent automation to accelerate innovation efforts, build competitive advantage, drive new business opportunities, and reduce costs.

250+ Speakers

120+ Sponsors

2700+Attendees

100+Sessions

SOURCE

From: “Dan Trajman @ NEIBC” <dan.trajman@neibc.org>

Reply-To: <dan.trajman@neibc.org>

Date: Wednesday, October 23, 2019 at 11:50 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Israeli Companies Presenting at AI World October 24, 2019

 

Event Brochure

https://aiworld.com/docs/librariesprovider28/agenda/19/aiworld-conference-expo-2019.pdf

 

Plenary Program

WEDNESDAY, OCTOBER 23

9:00 AM SUMMIT KICK OFF: AI Becomes Real

Scott Lundstrom, Group Vice President and General Manager, IDC

Government and Health Insights, IDC and AI World, Conference Co-Chair

 

9:10 AM SUMMIT KEYNOTE: Business Strategy with Artificial Intelligence

Sam Ransbotham, PhD, Professor, Academic Contributing Editor,

Information Systems, Boston College; MIT Sloan Management Review

 

9:35 AM EXECUTIVE ROUNDTABLE:

AI Drives Innovation in Enterprise Applications

Moderator: Mickey North-Rizza, Research Vice President, Enterprise Applications, IDC

Panelists:

David Castillo, PhD, Managing Vice President, Machine Learning, Capital One

Mukesh Dalal, PhD, Chief Analytics Officer & Chief Data Scientist, Bose Corporation

Madhumita Bhattacharyya, Managing Director – Enterprise Data & Analytics,

Protiviti Sasha Caskey, CTO & Co-Founder, Kasisto

 

10:05 AM KEYNOTE: Evolving Role of CDAOS in the New Era – An Organizational Construct

Anju Gupta, Vice President, Chief Data and Analytics Officer, Enterprise Holdings

 

10:30 – 10:50 AM NETWORKING BREAK

 

10:50 AM EXECUTIVE ROUNDTABLE:

 

The Evolution of Conversational Assistants

 

Moderator:

Reenita Malholtra Hora, Director of Marketing & Communications, SRI International

Panelists:

William Mark, PhD, President, SRI

Karen Myers, Lab Director, SRI International’s AI Center

 

11:20 AM Talk Title to be Announced

Genevy Dimitrion VP, Enterprise Data and Analytics, Humana

 

11:40 AM How AI Maturity Impacts a Winning Corporate Strategy

Ritu Jyoti, Program Vice President, IDC

 

4:20 PM PLENARY KEYNOTE PANEL:

Learning from XPRIZE Startups to Achieve Successful AI Innovation

Moderator:

Devin Krotman, Director, IBM Watson

AI XPRIZE,

XPRIZE Foundation

 

Panelists: Eleni Miltsakaki, Founder and CEO, Choosito

Ellie Gordon, Founder, CEO, & Designer, Behaivior AI

Daniel Fortin, President, AITera Inc.

 

12:00 PM LUNCHEON KEYNOTE:

Case Studies of Conversational AI – Real Deployments at Scale

Jim Freeze, Chief Marketing Officer, Interactions

 

Sponsored by Ben Bauks, Senior Business Systems Analyst, Constant Contact

 

THURSDAY, OCTOBER 24

 

8:20 AM BREAKFAST KEYNOTE:

The Promise and Pain of Computer Vision in Retail, Healthcare, and Agriculture

Ben Schneider, Vice President, Product, Alegion

 

9:00 AM CONFERENCE INTRODUCTION

Eliot Weinman, Founder & Conference Chair, AI World; Executive Editor, AI Trends

 

9:05 AM INTRODUCTORY REMARKS

Scott Lundstrom, Group Vice President and General Manager, IDC Government and

Health Insights, IDC and AI World, Conference Co-Chair

 

9:15 AM KEYNOTE PRESENTATION:

The Human Strategy

Alex Sandy Pentland, PhD, Professor, Engineering, Business, Media Lab, MIT

 

9:45 AM KEYNOTE:

Uber’s Intelligent Insights Assistant

Franziska Bell, PhD, Director, Data Science, Data Science Platforms, Uber

 

10:15 AM KEYNOTE:

AI in Finance: Present and Future, Hype and Reality

Charles Elkan, PhD, Managing Director, Goldman Sachs

 

10:40 – 11:00 AM COFFEE BREAK

 

11:00 AM KEYNOTE:

AI at Work in Legal, News and Tax & Accounting